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Hypercholesterolemia describes the presence of increased lipids 
in blood that is caused either by a predisposed genetic condi-
tion, such as a mutation of the LDL receptor (LDLR), or by an 
underlying disorder, such as obesity. Hypercholesterolemia is a 
major risk factor for atherosclerosis (1). The “response-to-inju-
ry” hypothesis (2) of atherosclerosis proposes that endothelial 
dysfunction allows circulating LDL to infiltrate the arterial wall, 
where it is progressively oxidized to form minimally modified 
LDL (mmLDL) and immunogenic oxidized LDL (oxLDL) (3, 4). 
Indeed, autoantibodies against oxLDL can be detected in hyper-
lipidemic mice and humans (4, 5). Although the majority of oxi-
dized lipoproteins are localized within atherosclerotic lesions, 
small quantities have been detected in the circulation of patients 
with coronary artery disease (6, 7).
mmLDL and oxLDL contain many oxidation products that form 
from both the oxidation and fragmentation of lipid and protein 
components (8). Monocytes recruited into the inflamed arterial wall 
internalize mmLDL via TLR4 and form lipid-laden foamy macro-
phages (9). OxLDL is recognized and internalized by macrophages 
via scavenger receptors (SRs), such as CD36 and SR-AI/II (10). A 
recent study found that oxLDL induction of chemokine expression 
in murine macrophages is mediated by a CD36/TLR4/TLR6 het-
erotrimeric receptor complex (11). Importantly, TLR4 expression 
on PBMCs and monocytes is increased in patients with advanced 
cardiovascular disease (12, 13), and circulating monocytes have been 
shown to accumulate mmLDL in a TLR4-dependent manner (9).
Hypercholesterolemia is associated with a prothrombotic state 
(14). Platelets are hyperactive in patients with hypercholester-
olemia (14, 15). A recent study demonstrated that activation of 
platelets with a specific oxidized choline glycerophospholipid 
(oxPCCD36) is mediated by CD36 (16). Moreover, hypercholesterol-
emic mice exhibit a shortened time to occlusion in a carotid artery 
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thrombosis model compared with healthy mice (16–19). At pres-
ent, the mechanism underlying the systemic activation of coagula-
tion associated with hypercholesterolemia has not been defined.
oxLDL and other bioactive lipids induce expression of the pro-
coagulant protein tissue factor (TF) in monocytes/macrophages, 
endothelial cells, and smooth muscle cells (20–24). Consistent with 
these in vitro observations, high levels of TF are present in human 
and mouse atherosclerotic plaques (25–28). In addition, TF expres-
sion is increased in monocytes of patients with familial hypercho-
lesterolemia (FH), who have high levels of plasma cholesterol due 
to mutations in the LDLR gene, and in monocytes of individuals 
with hypercholesterolemia (29–31). Furthermore, injection of oxi-
dized lipids into mice increased TF expression in blood cells (32). 
Microparticles (MPs) are small plasma membrane vesicles released 
from activated and apoptotic cells that contain proteins from their 
cell of origin (33). Interestingly, acute coronary syndrome patients 
have elevated levels of monocyte-derived MPs and TF+ MPs (34, 35). 
Atherosclerotic plaques also contain high levels of monocyte-
derived TF+ MPs (36), and cholesterol enrichment of human mono-
cytic cells has been shown to induce the release of TF+ MPs (37). 
These data suggest that TF expression by circulating monocytes 
and the release of TF+ MPs may contribute to the systemic proco-
agulant state associated with hypercholesterolemia.
Statins are used to treat hypercholesterolemic patients and not 
only lower levels of plasma cholesterol, but also induce plaque 
regression (38). Statins also have antiinflammatory and anti-
thrombotic activities (39, 40). Several studies have found that 
statin therapy is associated with a significant reduction in the inci-
dence of venous thromboembolism (VTE) (41–43). Interestingly, 
statins also inhibit TF expression in monocytes and macrophages, 
both in vitro and in vivo (27, 29, 31, 39, 44–47).
In this study, we investigated the mechanism by which hypercho-
lesterolemia leads to activation of coagulation in mice, monkeys, 
and humans and the effect of simvastatin administration.
Results
Levels of MP TF activity and activation of coagulation in FH patients before 
and after apheresis. We examined levels of MP TF activity and activa-
tion of coagulation in FH patients (n = 25) and healthy matched 
controls (n = 17). FH patients had elevated levels of plasma lip-
ids compared with healthy controls (except for HDL cholesterol 
[HDL-C]; Supplemental Table 1; supplemental material available 
online with this article; doi:10.1172/JCI58969DS1). FH patients 
also had elevated levels of oxLDL, MP TF activity, thrombin-anti-
thrombin complex (TAT), which is a marker of activation of coag-
ulation, and the inflammatory marker high-sensitivity C-reactive 
protein (hsCRP) compared with controls (Figure 1, A–D). Apher-
esis reduced all parameters (Figure 1, A–D).
oxLDL induction of monocytic TF expression and release of TF+ MPs. We 
determined the effect of LDL and oxLDL on TF expression in the 
human monocytic cell line THP-1 and human monocytes. OxLDL 
increased cellular TF activity in THP-1 cells at 24 hours in a concen-
tration-dependent manner (0–50 μg/ml) without affecting cell via-
bility (data not shown). Levels of oxLDL above 50 μg/ml decreased 
cell viability (data not shown). Therefore a dose of 50 μg/ml was 
chosen for all subsequent experiments. OxLDL, but not LDL, 
increased cellular TF activity in THP-1 cells in a time-dependent 
manner, with maximal levels observed at 8 hours (Figure 2A). Inter-
estingly, this response was delayed compared with the induction of 
TF expression in cells treated with LPS (Supplemental Figure 1A). 
OxLDL treatment also induced a time-dependent release of TF+ 
MPs into the culture supernatant, with maximal levels observed 
at 24 hours (Figure 2B). LPS induced a more rapid release of TF+ 
MPs (Supplemental Figure 1B). OxLDL also induced TF expres-
sion in isolated human monocytes (Figure 2E). The LPS inhibitor 
polymyxin B had no effect on oxLDL induction of TF expression in 
THP-1 cells or monocytes, but abolished the LPS response (Figure 2, 
C and E, and Supplemental Figure 1, C and E).
Simvastatin and a TLR4 inhibitor attenuate oxLDL induction of mono-
cytic TF expression. To determine whether oxLDL induction of TF 
expression was dependent on TLR4, we pretreated THP-1 cells and 
monocytes with the TLR4 inhibitor CLI-095 (TAK-242). Inhibition 
of TLR4 ablated oxLDL and LPS induction of cellular TF activity 
and the release of TF+ MPs from THP-1 cells (Figure 2, C and D, 
and Supplemental Figure 1, C and D) and monocytes (Figure 2, E 
and F, and Supplemental Figure 1, E and F).
Figure 1
Measurement of coagulation in FH patients. Blood 
was obtained from matched healthy controls (n = 17) 
and FH patients (n = 25). Preapheresis is defined 
as blood drawn from the body that has not yet 
passed over the lipid-absorbing column. Postapher-
esis blood was collected after lipid absorbing, but 
prior to reentering the body. (A) oxLDL, (B) MP TF 
activity, (C) TAT, and (D) hsCRP. Histobars repre-
sent mean ± SEM. *P < 0.025, FH patients versus 
healthy controls; #P < 0.01, FH patients before ver-
sus after apheresis. Data were analyzed with 1-way 
ANOVA on ranks with a Dunn’s post hoc.
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Statins have been shown to reduce LPS induction of TF expres-
sion in monocytes and macrophages. Therefore, we determined 
the effect of simvastatin on oxLDL induction of TF expression. 
Preincubation of THP-1 cells and monocytes with simvastatin 
decreased oxLDL induction of cellular TF activity and the release 
of TF+ MPs (Figure 2, C–F). Simvastatin also decreased LPS 
induction of TF expression in the cells (Supplemental Figure 1, 
C–F) and the basal level of cellular TF activity in unstimulated 
THP-1 cells (Figure 2C).
Hypercholesterolemia induces TF expression and activation of coagu-
lation in mice. We used LDLR-deficient (Ldlr–/–) mice fed a high-
fat/high-cholesterol diet (HFD/Western) for up to 12 weeks as 
a model of hypercholesterolemia. We observed a rapid increase 
in plasma cholesterol levels at 2 weeks, followed by a plateau 
(Figure 3A and Supplemental Table 2) and a time-dependent 
increase in plasma oxLDL (Figure 3B). Hypercholesterolemic 
mice also had an induction of wbc TF expression at 12 weeks 
(Figure 3C) and a time-dependent increase in MP TF activ-
ity, TAT, and D-dimer (Figure 3, D–F). The increase of MP TF 
activity was linearly correlated (Pearson’s correlation) with both 
TAT (r = 0.92, P < 0.001) and D-dimer (r = 0.86, P < 0.009). 
Finally, we found that the level of IL-6 and the number of MPs 
Figure 2
oxLDL induction of monocytic TF expression and the release of TF+ MPs. THP-1 cells were treated with LDL (50 μg/ml) or oxLDL (50 μg/ml) for 
different times, and (A) cellular TF activity and (B) MP TF activity in the culture supernatant were analyzed. THP-1 cells were treated for either 
8 hours and analyzed for (C) cellular TF activity or 24 hours and analyzed for (D) MP TF activity in the culture supernatant after pretreatment with 
simvastatin (20 μM, sim) for 12 hours, the TLR4 inhibitor TAK-242 (1 μg/ml) for 2 hours, or the LPS-neutralizing antibiotic peptide polymyxin B 
(10 μg/ml) for 30 minutes. Human monocytes were also pretreated with the same agents; (E) cellular TF activity was analyzed after 8 hours, 
and (F) MP TF activity in the culture supernatant was analyzed after 24 hours. Data are represented as mean ± SEM. All experiments were 
performed 5 times in triplicate. *P < 0.01, oxLDL-treated versus untreated and LDL-treated cells; #P < 0.01, simvastatin-treated versus untreated 
cells; †P < 0.001, simvastatin-treated or TAK-242–treated versus cells without inhibitor. Data in A and B were analyzed with 1-way ANOVA with 
Holm-Sidak post hoc, while data in C–F were analyzed via 2-way ANOVA with Holm-Sidak post hoc.
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were increased in a time-dependent manner in mice fed a HFD 
(Figure 3, G and H).
Simvastatin reduces TF expression and activation of coagulation in 
hypercholesterolemic mice. We examined the effect of administration 
of simvastatin on TF expression and activation of coagulation in 
hypercholesterolemic mice. Mice were fed a HFD for 12 weeks to 
activate coagulation and then fed a HFD containing simvastatin 
(50 mg/kg/d) for an additional 4 weeks. Simvastatin did not affect 
plasma cholesterol levels, weight, or other plasma lipids compared 
with 12 weeks of HFD (Figure 3A and Supplemental Table 2). In 
contrast, simvastatin significantly reduced 
levels of oxLDL, wbc TF expression, MP TF 
activity, IL-6, activation of coagulation, and 
the number of MPs (Figure 3, B–H).
Role of TF in the activation of coagulation in 
hypercholesterolemic mice. To directly examine 
the role of TF in the activation of coagula-
tion in hypercholesterolemic mice, we used 
an inhibitory rat anti-mouse TF monoclonal 
antibody (1H1) (48). Mice were fed a HFD 
for 12 weeks and then injected with either 
a rat anti-mouse TF antibody or a control 
rat IgG antibody. MP TF activity was sig-
nificantly reduced in mice treated with 1H1 
compared with mice treated with a control 
antibody (Figure 4A). In addition, inhibition 
of TF significantly reduced the activation of 
coagulation (Figure 4, B and C) and reduced 
the level of IL-6 (Figure 4D). No differences 
in lipid profiles were observed in mice treat-
ed with the anti-TF antibody compared with 
controls (Supplemental Table 2).
To assess the contribution of hematopoi-
etic cell TF to the elevated levels of TF+ MPs 
and activation of coagulation in hypercho-
lesterolemic mice, we performed a bone mar-
row transplantation experiment with cells 
deficient in TF expression. Irradiated Ldlr–/– 
mice were transplanted with bone marrow 
from either low TF mice (mTF–/–;hTF+), which 
express very low levels of TF (1% of wild-type 
levels), or bone marrow from heterozygous 
TF (TF+/–;hTF+) littermate control mice. Trans-
planted mice were fed a HFD for 12 weeks. 
Levels of MP TF activity and activation 
of coagulation were significantly lower in 
the hypercholesterolemic recipients that 
received low TF bone marrow compared with 
mice containing control marrow (Figure 5, 
A–C). A deficiency of hematopoietic cell TF 
was also associated with a reduction in the 
level of IL-6, although this reduction did not 
achieve significance (Figure 5D; P = 0.08). No 
differences in lipid profiles were observed in 
irradiated mice that received low TF bone 
marrow compared with controls (Supple-
mental Table 2).
Analysis of thrombosis in hypercholesterolemic 
mice. We found that hypercholesterolemia is 
associated with a shorter time to occlusion, 
utilizing the ferric chloride (5%) model of arterial thrombosis 
(Supplemental Figure 2A). The addition of an anti-TF antibody 
increased the time to occlusion in these hypercholesterolemic 
mice (Supplemental Figure 2A). In addition, simvastatin treat-
ment prolonged the time to occlusion in chow and HFD-fed 
Ldlr–/– mice (Supplemental Figure 2B). However, hypercholester-
olemia increases TF expression in the vessel wall and also acti-
vates platelets (15, 16, 28). Therefore, we could not determine 
the contribution of elevated levels of TF+ MPs to the shortened 
occlusion time observed in these models.
Figure 3
Simvastatin attenuates hypercholesterolemic activation of coagulation in mice. Ldlr–/– mice 
were fed a HFD for up to 12 weeks and then fed a HFD with simvastatin (50 mg/kg/d) for an 
additional 4 weeks (16 weeks total). (A) Total plasma cholesterol (TPC), (B) oxLDL, (C) wbc 
TF activity, (D) MP TF activity, (E) TAT, (F) D-dimer, (G) IL-6, and (H) PS+ MPs. Histobars 
represent means ± SEM of 5 mice per group (HFD) or 10 mice per group (simvastatin). 
*P < 0.01, HFD versus 0-week control (chow). #P < 0.05, simvastatin treated versus week 12. 
Data were analyzed with 1-way ANOVA on ranks with Dunn’s post hoc (A and D–G) or 1-way 
ANOVA with Holm-Sidak post hoc (B, C, and H).
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To more specifically analyze the role of the elevated levels of circu-
lating TF+ MPs in thrombosis, we used the laser-injury cremaster arte-
riole model of thrombosis. We have found that low levels of hema-
topoietic cell–derived TF+ MPs present in healthy mice contribute to 
fibrin deposition in this model (49). We observed that fibrin accumu-
lation in hypercholesterolemic mice was significantly increased com-
pared with that in mice on a chow diet (Figure 6A). Representative 
images of fibrin deposition in chow and HFD-fed mice are shown 
in Figure 6, B and C, respectively. Similarly, we observed increased 
platelet accumulation in injured vessels of hypercholesterolemic 
mice compared with controls (Figure 6, D–F).
Role of TLR4 and TLR6 in the induction of TF expression in hypercho-
lesterolemic mice. A recent study demonstrated that oxLDL binding 
to a CD36/TLR4/TLR6 heterotrimeric complex on macrophages 
and monocytic cells induces various chemokines (11). To deter-
mine whether hypercholesterolemic induction of TF expression 
and activation of coagulation are mediated by a similar complex, 
we used Ldlr–/– mice deficient in either TLR4 or TLR6. We found 
that an absence of either TLR4 or TLR6 dramatically reduced lev-
els of MP TF activity and activation of coagulation in hypercho-
lesterolemic mice (Figure 7, A–C). Furthermore, TF activity of wbc 
isolated from these hypercholesterolemic Tlr4–/– or Tlr6–/– mice 
was significantly reduced (n = 6 per group; P < 0.001, data not 
shown) compared with wbc TF expression of littermate Tlr4+/+ or 
Tlr6+/+ controls. The high level of IL-6 observed in hypercholester-
olemic mice was also significantly reduced in mice lacking TLR4 
or TLR6 (Figure 7D).
Induction of TF expression and activation of coagulation in hypercho-
lesterolemic monkeys and the effect of simvastatin. We extended the 
mouse studies by examining hypercholesterolemic induction of 
PBMC TF expression, MP TF activity, and activation of coagula-
tion in a nonhuman primate model. We used African green mon-
keys fed a HFD for 16 weeks (Supplemental Table 3). Monkeys 
fed a HFD for a 16-week period had elevated levels of total plasma 
Figure 4
Activation of coagulation in hypercholesterolemic 
mice is TF dependent. Ldlr–/– mice were fed a 
HFD for 12 weeks and injected with either a rat 
anti-mouse TF monoclonal antibody or a rat IgG 
control. (A) MP TF activity, (B) TAT, (C) D-dimer, 
(D) IL-6. Histobars represent mean ± SEM of 
n = 7 mice per group. *P < 0.001, rat anti-mouse 
TF treatment versus rat IgG. Data were analyzed 
using either a 2-tailed Student’s t test (A–C) or a 
Mann-Whitney rank sum (D).
Figure 5
Hematopoietic cell TF deficiency attenuates activa-
tion of coagulation in hypercholesterolemic mice. 
Irradiated Ldlr–/– mice were repopulated with either 
TF+/– or low TF bone marrow. Mice were fed either 
chow (n = 7 each group) or HFD (TF+/– n = 10, low 
TF n = 9) for 12 weeks and (A) MP TF activity, (B) 
TAT, (C) D-dimer, and (D) IL-6 were measured. 
Histobars represent mean ± SEM. *P < 0.001, TF+/– 
HFD versus other groups; #P < 0.001, low TF HFD 
versus TF+/– HFD; †P = 0.08 low TF HFD versus 
TF+/– HFD. Data were analyzed with 2-way ANOVA 
with a Holm-Sidak post hoc.
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cholesterol, VLDL-C, and LDL-C compared with chow-fed con-
trols (Supplemental Figure 3, A–C, and Supplemental Table 4). 
Levels of HDL-C and triglycerides remained unchanged during 
the course of the study (Supplemental Figure 3D and Supplemen-
tal Table 4). Unlike the rapid increase and plateau observed with 
LDL-C, we observed a time-dependent increase in oxLDL after 
feeding the monkeys a HFD (Figure 8A). Prolonged hypercho-
lesterolemia in the monkeys resulted in an increase in PBMC TF 
activity (Supplemental Figure 3F) and a time-dependent increase 
in MP TF activity and activation of coagulation (Figure 8, B–D). 
We also found that hypercholesterolemia significantly increased 
TF mRNA expression in PMBCs (Supplemental Figure 4A). Simi-
larly, hypercholesterolemia induced TLR4, TLR6, and CD36 mRNA 
expression in PBMCs (Supplemental Figure 4, B–D). Next, we 
analyzed markers of inflammation and levels of MPs in hypercho-
lesterolemic monkeys. IL-6 was not increased in hypercholesterol-
emic monkeys (data not shown). Therefore, we measured levels of 
the inflammatory markers hsCRP and IL-8. hsCRP and IL-8 were 
time dependently increased with hypercholesterolemia (Figure 8, 
E and F). Finally, we observed a time-dependent increase in the 
number of MPs and elevation of total particles in hypercholester-
olemic monkeys (Figure 8, G and H).
To determine the effect of simvastatin, monkeys were fed a 
HFD for 16 weeks followed by 4 weeks with a HFD containing 
simvastatin (10 mg/kg/day). To confirm the bioavailability of 
simvastatin, we examined plasma levels of proprotein conver-
tase subtilisin kexin type 9 (PCSK9), which increases after statin 
administration as a compensatory mechanism to increase circu-
lating LDL (50). PCSK9 was elevated by 60% in monkeys receiving 
simvastatin compared with controls (Supplemental Figure 3E). 
Simvastatin administration did not affect levels of plasma lipids 
and lipoprotein cholesterol (Supplemental Figure 3, A–D, and 
Supplemental Table 4). However, similar to the mouse studies, 
simvastatin reduced levels of PBMC TF expression, oxLDL, MP TF 
activity, TAT, and D-dimer in the hypercholesterolemic monkeys 
(Figure 8, A–D, and Supplemental Figure 3F). In addition, simvas-
tatin reduced the inflammatory markers and the number of MPs 
and particles (Figure 8, E–H).
Discussion
In this study, we found that oxLDL induced TF expression in 
THP-1 monocytic cells and human monocytes in a TLR4-depen-
dent manner. Furthermore, FH patients had elevated levels of 
both oxLDL and MP TF activity as well as activation of coag-
ulation. We found that levels of MP TF activity increased in a 
time-dependent manner in parallel to markers of activation of 
coagulation in Ldlr–/– mice and monkeys fed a HFD. Hypercho-
lesterolemia was also associated with increased fibrin deposition 
in a mouse model of microvascular thrombosis in which hema-
topoietic cell–derived TF+ MPs contribute to thrombosis (49). 
TF was responsible for the procoagulant state in hypercholester-
olemic mice because inhibition of TF reduced the activation of 
coagulation. We found that a genetic deficiency of TF in hemato-
poietic cells dramatically reduced the activation of coagulation in 
Figure 6
Hypercholesterolemia increases fibrin deposition and platelet accumulation in a laser-induced cremaster arteriole model of thrombosis. Male 
Ldlr–/– mice fed either chow or HFD for 12 weeks (n = 3 mice per group) underwent cremaster arteriole laser injury (chow, 24 thrombi; HFD, 
20 thrombi). (A) Fibrin and (D) platelet deposition were measured by intravital microscopy in which median fluorescent units (MFU) represented as 
AU were plotted against time for 200 seconds. Representative combined binarized fluorescence and bright field microscopy images of peak fibrin 
deposition in chow-fed (B) and HFD-fed (C) mice labeled with a fibrin-specific antibody conjugated to Alexa Fluor 647 (red) or peak platelet accu-
mulation in chow-fed (E) and HFD-fed (F) mice labeled with an anti-CD42b antibody conjugated to DyLight 488 (green). *P < 0.05 fibrin HFD versus 
chow and platelet HFD versus chow. Data analyzed as AUC with a Mann-Whitney rank sum. Original magnification, ×60. Scale bars: 10 μm.
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hypercholesterolemic mice, which is consistent with the notion 
that monocytes are the primary source of pathologic TF expres-
sion in this model. In contrast, we recently found that activation 
of coagulation in a mouse model of endotoxemia was dependent 
on TF expression by both hematopoietic and nonhematopoietic 
cells (51). These results indicate that different cellular sources of 
TF contribute to the activation of coagulation in different patho-
logic states. This information is important for developing novel 
anticoagulant strategies that can inhibit inducible TF expression 
in specific cell types, such as monocytes, to reduce thrombosis.
Many studies have demonstrated that activation of the coagulation 
system can enhance inflammation in different diseases (52). Studies 
with septic baboons showed that inhibition of TF reduced IL-6 and 
IL-8 expression (53). In addition, we found that levels of IL-6 were 
reduced in endotoxemic mice with 1% TF expression compared with 
littermate controls with 50% levels of TF (54). In the current study, 
we found that inhibition of TF reduced levels of IL-6 in hypercholes-
terolemic mice. These results indicate that there is crosstalk between 
coagulation and inflammation during hypercholesterolemia.
Recent studies have demonstrated detectable levels of mmLDL 
and oxLDL in the circulation (6, 7). Indeed, several studies have 
demonstrated circulating oxidized lipids can be predictive of the 
presence, progression, and regression of cardiovascular disease (55, 
56). We detected oxLDL in the circulation of hyperlipidemic mice, 
monkeys, and humans. In mice and monkeys, oxLDL in the plasma 
increased in a time-dependent manner after feeding a HFD. These 
results indicate that small amounts of mmLDL and oxLDL are 
present in the circulation during hypercholesterolemia and likely 
activate circulating monocytes.
oxLDL induction of inflammatory mediators in murine macro-
phages was recently shown to be mediated by a CD36/TLR4/TLR6 
heterotrimeric complex (11). Human THP-1 monocytic cells and 
human monocytes were also found to contain the same complex (11). 
Moreover, in patients with advanced cardiovascular disease, TLR4 
expression is increased on PBMCs and monocytes by an undefined 
mechanism (12, 13). Our studies with both THP-1 cells and human 
monocytes demonstrated that oxLDL induction of TF expression 
and release of TF+ MPs required TLR4. Moreover, we found that a 
deficiency of either TLR4 or TLR6 was associated with reduced TF 
and IL-6 expression and systemic activation of coagulation in hyper-
cholesterolemic mice. We found that prolonged hyperlipidemia 
increased TF, TLR4, TLR6, and CD36 mRNA expression in circulat-
ing monkey PBMCs, which is similar to the increased expression 
of TLR4 in monocytes of advanced cardiovascular disease patients 
(12, 13). These results indicate that hypercholesterolemia leads to 
the generation of oxLDL and the increased expression of the CD36/
TLR4/TLR6 heterotrimeric complex on circulating monocytes. We 
propose that this complex is then activated by oxLDL, leading to the 
induction of both TF and IL-6 expression and the development of a 
prothrombotic and proinflammatory state (Figure 9).
Simvastatin and rosuvastatin have been shown to reduce TF 
expression in the aorta and atherosclerotic lesions of hyper-
cholesterolemic mice without reducing lipid levels (27, 39). In 
addition, simvastatin and pravastatin reduced inflammation 
and thrombogenicity in hypercholesterolemic pigs and mon-
keys without affecting cholesterol levels (57, 58). Simvastatin 
pretreatment was also shown to reduce LPS induction of mono-
cyte TF expression and inflammation in healthy human vol-
unteers (46). The JUPITER trial showed that administration of 
rosuvastatin to individuals with normal LDL but elevated levels 
of hsCRP significantly reduced the incidence of major cardio-
vascular events and symptomatic VTE (59). It was speculated 
that the reduction in thrombosis was due to statin inhibition 
of TF expression, but this was not analyzed (59). In our study, 
we found that simvastatin inhibited oxLDL induction of TF 
expression in THP-1 cells and human monocytes. In hypercho-
lesterolemic mice and monkeys, simvastatin therapy reduced the 
levels of oxLDL independent of any effect on LDL-C or total 
cholesterol. This could be due to either the inhibition of oxida-
tive modification of LDL or via mobilization and clearance of 
proinflammatory oxidized phospholipids (60–62). Furthermore, 
simvastatin treatment of hypercholesterolemic mice and mon-
keys also reduced wbc and PBMC TF expression, MP TF activ-
ity, and activation of coagulation (Figure 9). TLR4, TLR6, and 
CD36 mRNA expression in circulating PBMCs was also reduced 
in statin-treated monkeys, which is similar to simvastatin- and 
rosuvastatin-induced decreases in human monocytes express-
ing TLR4 (63). Our results suggest that the ability of statins to 
reduce TF may explain the mechanism by which statins reduce 
VTE in hypercholesterolemic patients.
Figure 7
TLR4 and TLR6 deficiency attenuate activation of coagu-
lation in hypercholesterolemic mice. Ldlr–/–Tlr4+/+ (chow, 
n = 6; HFD, n = 10), Ldlr–/–Tlr4–/– (chow, n = 8; HFD, n = 26), 
Ldlr–/–Tlr6+/+ (chow and HFD, n = 7), and Ldlr–/–Tlr6–/– (chow, 
n = 6; HFD, n = 13) mice were fed either a chow diet or HFD 
for 12 weeks. (A) MP TF activity, (B) TAT, (C) D-dimer, and 
(D) IL-6. Histobars represent mean ± SEM. *P < 0.001, 
Tlr4+/+ or Tlr6+/+ versus other groups; #P < 0.001, Tlr4–/– or 
Tlr6–/– HFD versus Tlr4+/+ or Tlr6+/+ HFD. Data were ana-
lyzed with 2-way ANOVA with a Holm-Sidak post hoc test.
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Methods
Addition information is provided in Supplemental Methods.
Cell culture. Human monocytic THP-1 cells were obtained from ATCC. 
Cells were grown in RPMI-1640 supplemented with 10% FBS, 1 mM sodium 
pyruvate, 1 mM HEPES, 1% glucose, and 1% penicillin/streptomycin. Cells 
were treated with native LDL or oxLDL obtained from Biomedical Tech-
nologies Inc. The TLR4 inhibitor CLI-095 was obtained from Invivogen. 
The carboxylate (activated) form of simvastatin was purchased from Calbio-
chem. Polymyxin B and LPS (E. coli; 0111:B4) were purchased from Sigma-
Aldrich. Viability was assessed using the alamarBlue Assay (Invitrogen).
Human monocyte isolation. Human blood was collected into BD glass vacu-
tainers (3.2% sodium citrate), and PBMCs were isolated using Ficoll-Paque 
Plus (GE Healthcare) from 5 separate donors. Human monocytes were iso-
lated by negative selection (Monocyte Isolation Kit II; Miltenyi Biotech).
Clotting assay and MP TF activity assay. The TF activity of cell lysates 
was measured using a 1-stage clotting assay with a STart 4 Clotting 
Figure 8
Simvastatin attenuates activation of coagulation in hypercholesterolemic monkeys. African green monkeys were switched from a chow diet 
(0 weeks) to a HFD for 16 weeks before being fed a HFD containing simvastatin (10 mg/kg/d) for an additional 4 weeks (20 weeks total). Blood 
samples were collected at 0–20 weeks. (A) oxLDL, (B) MP TF activity, (C) TAT, (D) D-dimer, (E) hsCRP, (F) IL-8, (G) PS+ MPs, and (H) number of 
particles were measured. Histobars represent mean ± SEM of 12 monkeys. *P < 0.05, HFD versus chow; #P < 0.001, simvastatin treated versus 
16 weeks. Data were analyzed with either 1-way ANOVA with a Holm-Sidak post hoc (A–C, E, and F) or 1-way ANOVA on ranks (D, G, and H).
Figure 9
Proposed sites of action of simvastatin that reduce TF expression and 
activation of coagulation during hypercholesterolemia. In humans, but 
not mice or monkeys, statins reduce plasma cholesterol levels. In addi-
tion, our results indicate that simvastatin reduces activation of coagula-
tion by inhibiting the oxidation of LDL, inhibiting the expression of the 
CD36/TLR4/TLR6 complex, and inhibiting monocyte TF expression 
and the release of TF+ MPs.
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Machine (Diagnostica Stago), as described (51). MP TF activity was 
measured as described (64).
Human subjects. Human subjects with FH were recruited at the Univer-
sity of Kansas Medical Center. The patient demographics are described 
in Supplemental Table 1. Apheresis was conducted as previously 
described (65). Control plasma samples (n = 17) were purchased from 
Innovative Research and were matched for age, sex, and race (Supple-
mental Table 1).
Mice and diet. Male Ldlr–/– mice were obtained from The Jackson Labo-
ratory. Ldlr–/–Tlr4+/+ and Ldlr–/–Tlr4–/– littermate mice were generated by 
interbreeding Ldlr–/–Tlr4+/– mice. The same strategy was used to generate 
Ldlr–/–Tlr6+/+ and Ldlr–/–Tlr6–/– littermates. mTF–/–;hTF+ (low TF) mice and 
littermate TF+/–;hTF+ controls were used as donors in bone marrow trans-
plant experiments (66). To induce hypercholesterolemia, mice were fed a 
diet enriched with saturated milk fat (21% w/w) and cholesterol (0.15% w/w; 
diet TD.88137 from Harlan Teklad). Simvastatin (50 mg/kg/d) was admin-
istered in the diet, as described (27). Blood was collected and processed as 
previously described (51, 64). Then wbc were isolated by lysing erythrocytes 
using an ammonium chloride solution.
Bone marrow transplantation. Male recipient Ldlr–/– mice (8 weeks old) were 
irradiated with a total of 11 Gy (2 doses of 550 rads 4 hours apart) using 
a Cs137 irradiator (J.L. Shepherd). Irradiated mice were repopulated with 
bone marrow (2 × 106 cells per animal) harvested from TF+/– (n = 17) or 
low-TF (n = 16) donor mice via retroorbital injection. Mice were allowed to 
recover for 4 weeks and then either fed a HFD (n = 10, TF+/–; n = 9, low TF) 
or chow (n = 7, TF+/– and low TF) for 12 weeks.
Inhibition of TF. Male Ldlr–/– mice (n = 14) were fed a HFD for 12 weeks 
and then split into 2 equal groups. One group received intraperitoneal 
injections of a rat anti-mouse TF monoclonal antibody (1H1, 20 mg/kg), 
while the other received the isotype control antibody (rat IgG2a; 20 mg/kg; 
Sigma-Aldrich). Injections were performed on day 0 and day 3, and mice 
were then euthanized and blood collected on day 6.
Monkeys and diet. Adult male African green monkeys (Chlorocebus 
aethiops) (n = 12, age 5–10 years) were obtained from St. Kitts Island. 
Monkeys were housed under the care of the Wake Forest University 
Health Sciences (WFUHS) Animal Resources Program. Monkeys were 
fed either a chow diet (Monkey Diet 5038; Lab Diet) or a HFD semi-
synthetic diet (Supplemental Table 3) to induce hypercholesterolemia. 
The monkeys were then fed a HFD containing simvastatin (10 mg/kg/d; 
Supplemental Table 3), which was provided by Merck and Co. Monkeys 
were sedated with 10 mg/kg ketamine. and blood was drawn into Vacu-
tainers containing sodium citrate (3.2% sodium citrate; BD). Blood was 
spun at 1,500 g for 15 minutes to prepare plasma and stored at –80°C. 
Monkey PBMCs were isolated using the same protocol as used for the 
isolation of human PBMCs.
ELISA measurements. The following commercial kits were used: mouse 
IL-6 and human IL-8 (R&D Systems), human oxLDL (Caymen Chemicals), 
human hsCRP (ALPCO Immunoassays), human D-dimer (Diagnostica 
Stago), and TAT Enzygnost Micro Kit (Dade Behring/Siemens).
PCSK9 analysis. Plasma PCSK9 levels were determined using an in-house 
ELISA from Merck Pharmaceuticals. A capture antibody (E07) and a bio-
tinylated secondary antibody (B20) were utilized for detection of PCSK9. 
Standard curves (11-point 2-fold dilutions from 1 μg/ml) were generated 
using purified African green monkey PCSK9.
Plasma lipid analysis. Human and mouse plasma lipids were analyzed 
with the following commercial kits: total plasma cholesterol (Total Cho-
lesterol E), triglycerides (L-Type TG M), and HDL-C (L-Type HDL-C) 
from Wako Chemicals. LDL-C was calculated using the Friedewald 
equation. VLDL-C was then calculated by subtracting HDL-C and 
LDL-C from total plasma cholesterol. Monkey total plasma cholesterol 
and triglycerides were measured using the Pointe Scientific Cholester-
ol Reagent Set and the L-type TG M assay (Wako Chemicals), respec-
tively. Plasma lipoprotein cholesterol distribution was determined as 
described previously (67).
Measurements of mouse plasma oxLDL. OxLDL was measured in the mouse 
plasma as previously described (68).
Ferric chloride carotid arterial thrombosis model. Ferric chloride carotid arte-
rial thrombosis was performed as described (16).
Laser-injury thrombosis model. Intravital microscopy, laser-induced cremas-
ter vessel-wall injury, and intravital imaging have been described (49).
Measurement of MPs. Plasma MPs were evaluated utilizing a phosphati-
dylserine (PS) capture and prothrombinase complex thrombin genera-
tion assay (Zymuphen MP Activity; Aniara). The results are expressed in 
PS equivalents (nM). The particle count in plasma was measured using the 
NanoSight NS500 system (NanoSight), which focuses a laser beam through 
the plasma, as described (69).
Real-time PCR analysis of monkey PBMCs. Total RNA was extracted from 
monkey PBMCs in TRIzol (Invitrogen). cDNA was synthesized, and real-
time PCR performed as previously described (51). TF, TLR4, and CD36 Taq-
Man primers were obtained from Applied Biosystems, while TLR6 FAM-
labeled primers were purchased from Integrated DNA Technologies.
Statistics and data representation. All bar and line graphs were created with 
Sigma Plot v.11 (SPSS). All statistical analysis was performed using Sig-
maStat, now incorporated into Sigma Plot v.11. Data are represented as 
mean ± SEM. For 2-group comparison of parametric data, a 2-tailed Stu-
dent’s t test was performed, while nonparametric data were analyzed with a 
Mann-Whitney rank sum. Statistical significance between multiple groups 
was assessed by ANOVA on ranks with a Dunn’s post hoc, 1-way ANOVA 
with Holm Sidak post hoc, or 1-way ANOVA with Holm Sidak post hoc, 
when appropriate. P < 0.05 was considered statistically significant.
Study approval. All mouse studies were performed with the approval of 
the University of North Carolina IACUC. All studies with monkeys were 
approved by the Wake Forest University School of Medicine IACUC. All 
patients and controls provided written informed consent in accordance 
with University of Kansas Medical Center and University of North Car-
olina Institutional Review Board (IRB) protocols for plasma and mono-
cyte isolation, respectively.
Note added in proof. After the submission of this manuscript, a study 
demonstrated a role of hematopoietic cell TF in diet-induced obesity 
(70). We similarly observed that Ldlr–/– mice reconstituted with TF-defi-
cient bone marrow and fed a HFD exhibited less weight gain (Supple-
mental Table 2), less epididymal and retroperitoneal fat pad weight 
(unpublished data), and less total adipocity (unpublished data) com-
pared with mice reconstituted with control bone marrow. Our results 
are consistent with the conclusion that hematopoietic cell TF signaling 
promotes obesity.
Acknowledgments
We thank Kathryn L. Kelley, Jessica Warden, D. Anthony Barcel, 
and Rebecca Lee for their skilled technical assistance. We would 
like to thank L. Petersen (Novo Nordisk) for providing mouse 
FVIIa. This work was supported by NIH grants PO1-HL006350 
(to N. Mackman), R01-HL095096 (to N. Mackman), R00-
HL088528 (to R.E. Temel), R01-HL086674 (to S. Nagarajan), 
P01-HL087203 (to B. Furie), R01-HL092125 (to B.C. Furie), 
and AHA50608351216 (to J.P. Luyendyk). A. Phillip Owens III 
was supported by an American Heart Association Mid-Atlan-
tic postdoctoral fellowship (09POST2250515) and is currently 
supported by a NIH F32 NRSA postdoctoral fellowship (1F32-
HL099175-01). F. Passam is a recipient of an American Society 
research article
	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 122   Number 2   February 2012 567
of Hematology–European Hematology Association Interna-
tional Exchange fellowship.
Received for publication May 12, 2011, and accepted in revised 
form November 9, 2011.
Address correspondence to: Nigel Mackman, University of North 
Carolina at Chapel Hill, 98 Manning Drive, Campus Box 7035, 
Chapel Hill, North Carolina 27599, USA. Phone: 919.843.3961; 
Fax: 919.966.7639; E-mail: nmackman@med.unc.edu.
 1. Stamler J, Wentworth D, Neaton JD. Is relationship 
between serum cholesterol and risk of premature 
death from coronary heart disease continuous and 
graded? Findings in 356,222 primary screenees 
of the Multiple Risk Factor Intervention Trial 
(MRFIT). JAMA. 1986;256(20):2823–2828.
 2. Ross R. Atherosclerosis--an inflammatory disease. 
N Engl J Med. 1999;340(2):115–126.
 3. Williams KJ, Tabas I. The response-to-retention 
hypothesis of early atherogenesis. Arterioscler 
Thromb Vasc Biol. 1995;15(5):551–561.
 4. Palinski W, Tangirala RK, Miller E, Young SG, 
Witztum JL. Increased autoantibody titers against 
epitopes of oxidized LDL in LDL receptor-deficient 
mice with increased atherosclerosis. Arterioscler 
Thromb Vasc Biol. 1995;15(10):1569–1576.
 5. Tsimikas S, Palinski W, Witztum JL. Circulating 
autoantibodies to oxidized LDL correlate with arte-
rial accumulation and depletion of oxidized LDL 
in LDL receptor-deficient mice. Arterioscler Thromb 
Vasc Biol. 2001;21(1):95–100.
 6. Holvoet P, Vanhaecke J, Janssens S, Van de Werf F, 
Collen D. Oxidized LDL and malondialdehyde-mod-
ified LDL in patients with acute coronary syndromes 
and stable coronary artery disease. Circulation.  
1998;98(15):1487–1494.
 7. Tsimikas S, Witztum JL. Measuring circulating oxi-
dized low-density lipoprotein to evaluate coronary 
risk. Circulation. 2001;103(15):1930–1932.
 8. Witztum JL, Steinberg D. Role of oxidized low den-
sity lipoprotein in atherogenesis. J Clin Invest. 1991; 
88(6):1785–1792.
 9. Choi SH, et al. Lipoprotein accumulation in mac-
rophages via toll-like receptor-4-dependent fluid 
phase uptake. Circ Res. 2009;104(12):1355–1363.
 10. Kunjathoor VV, et al. Scavenger receptors class A-I/
II and CD36 are the principal receptors responsible 
for the uptake of modified low density lipoprotein 
leading to lipid loading in macrophages. J Biol 
Chem. 2002;277(51):49982–49988.
 11. Stewart CR, et al. CD36 ligands promote sterile 
inflammation through assembly of a Toll-like 
receptor 4 and 6 heterodimer. Nat Immunol. 2010; 
11(2):155–161.
 12. Geng HL, et al. Increased expression of Toll like 
receptor 4 on peripheral-blood mononuclear cells 
in patients with coronary arteriosclerosis disease. 
Clin Exp Immunol. 2006;143(2):269–273.
 13. Methe H, Kim JO, Kofler S, Weis M, Nabauer M, 
Koglin J. Expansion of circulating Toll-like receptor 
4-positive monocytes in patients with acute coronary 
syndrome. Circulation. 2005;111(20):2654–2661.
 14. Lacoste L, Lam JY, Hung J, Letchacovski G, Solymoss 
CB, Waters D. Hyperlipidemia and coronary disease. 
Correction of the increased thrombogenic poten-
tial with cholesterol reduction. Circulation. 1995; 
92(11):3172–3177.
 15. Kaul S, Waack BJ, Padgett RC, Brooks RM, Heis-
tad DD. Altered vascular responses to platelets 
from hypercholesterolemic humans. Circ Res. 1993; 
72(4):737–743.
 16. Podrez EA, et al. Platelet CD36 links hyperlipidemia, 
oxidant stress and a prothrombotic phenotype.  
Nat Med. 2007;13(9):1086–1095.
 17. Eitzman DT, Westrick RJ, Xu Z, Tyson J, Ginsburg 
D. Hyperlipidemia promotes thrombosis after 
injury to atherosclerotic vessels in apolipoprotein 
E-deficient mice. Arterioscler Thromb Vasc Biol. 2000; 
20(7):1831–1834.
 18. Ghosh A, et al. Platelet CD36 mediates interac-
tions with endothelial cell-derived microparticles 
and contributes to thrombosis in mice. J Clin Invest. 
2008;118(5):1934–1943.
 19. Day SM, et al. Macrovascular thrombosis is driven 
by tissue factor derived primarily from the blood 
vessel wall. Blood. 2005;105(1):192–198.
 20. Bochkov VN, et al. Oxidized phospholipids stimu-
late tissue factor expression in human endothelial 
cells via activation of ERK/EGR-1 and Ca(++)/
NFAT. Blood. 2002;99(1):199–206.
 21. Schuff-Werner P, Claus G, Armstrong VW, Koster-
ing H, Seidel D. Enhanced procoagulatory activity 
(PCA) of human monocytes/macrophages after in 
vitro stimulation with chemically modified LDL. 
Atherosclerosis. 1989;78(2–3):109–112.
 22. Drake TA, Hannani K, Fei HH, Lavi S, Berliner 
JA. Minimally oxidized low-density lipoprotein 
induces tissue factor expression in cultured human 
endothelial cells. Am J Pathol. 1991;138(3):601–607.
 23. Meisel SR, et al. Dose-dependent modulation of 
tissue factor protein and procoagulant activity in 
human monocyte-derived macrophages by oxidized 
low density lipoprotein. J Atheroscler Thromb. 2011; 
18(7):596–603.
 24. Cui MZ, Penn MS, Chisolm GM. Native and oxi-
dized low density lipoprotein induction of tissue 
factor gene expression in smooth muscle cells is 
mediated by both Egr-1 and Sp1. J Biol Chem. 1999; 
274(46):32795–32802.
 25. Thiruvikraman SV, Guha A, Roboz J, Taubman 
MB, Nemerson Y, Fallon JT. In situ localization of 
tissue factor in human atherosclerotic plaques by 
binding of digoxigenin-labeled factors VIIa and X. 
Lab Invest. 1996;75(4):451–461.
 26. Wilcox JN, Smith KM, Schwartz SM, Gordon D. 
Localization of tissue factor in the normal vessel 
wall and in the atherosclerotic plaque. Proc Natl 
Acad Sci U S A. 1989;86(8):2839–2843.
 27. Bea F, Blessing E, Shelley MI, Shultz JM, Rosen-
feld ME. Simvastatin inhibits expression of tis-
sue factor in advanced atherosclerotic lesions of 
apolipoprotein E deficient mice independently of 
lipid lowering: potential role of simvastatin-medi-
ated inhibition of Egr-1 expression and activation. 
Atherosclerosis. 2003;167(2):187–194.
 28. Westrick RJ, Bodary PF, Xu Z, Shen YC, Broze GJ, 
Eitzman DT. Deficiency of tissue factor pathway 
inhibitor promotes atherosclerosis and thrombosis 
in mice. Circulation. 2001;103(25):3044–3046.
 29. Ferro D, Basili S, Alessandri C, Mantovani B, Cordo-
va C, Violi F. Simvastatin reduces monocyte-tissue-
factor expression type IIa hypercholesterolaemia.  
Lancet. 1997;350(9086):1222.
 30. Puccetti L, Bruni F, Bova G, Cercignani M, Pom-
pella G, Auteri A, Pasqui AL. Role of platelets in tis-
sue factor expression by monocytes in normal and 
hypercholesterolemic subjects. In vitro effect of 
cerivastatin. Int J Clin Lab Res. 2000;30(3):147–156.
 31. Ferro D, Basili S, Alessandri C, Cara D, Violi F. Inhibi-
tion of tissue-factor-mediated thrombin generation 
by simvastatin. Atherosclerosis. 2000;149(1):111–116.
 32. Kadl A, Huber J, Gruber F, Bochkov VN, Binder BR, 
Leitinger N. Analysis of inflammatory gene induc-
tion by oxidized phospholipids in vivo by quantita-
tive real-time RT-PCR in comparison with effects 
of LPS. Vascul Pharmacol. 2002;38(4):219–227.
 33. Owens AP 3rd, Mackman N. Microparticles 
in hemostasis and thrombosis. Circ Res. 2011; 
108(10):1284–1297.
 34. Matsumoto N, Nomura S, Kamihata H, Kimura Y, 
Iwasaka T. Increased level of oxidized LDL-dependent 
monocyte-derived microparticles in acute coronary 
syndrome. Thromb Haemost. 2004;91(1):146–154.
 35. Morel O, et al. Increased levels of procoagulant 
tissue factor-bearing microparticles within the 
occluded coronary artery of patients with ST-
segment elevation myocardial infarction: role of 
endothelial damage and leukocyte activation.  
Atherosclerosis. 2009;204(2):636–641.
 36. Leroyer AS, et al. Cellular origins and thrombogen-
ic activity of microparticles isolated from human 
atherosclerotic plaques. J Am Coll Cardiol. 2007; 
49(7):772–777.
 37. Liu ML, Reilly MP, Casasanto P, McKenzie SE, 
Williams KJ. Cholesterol enrichment of human 
monocyte/macrophages induces surface exposure 
of phosphatidylserine and the release of biologi-
cally-active tissue factor-positive microvesicles. 
Arterioscler Thromb Vasc Biol. 2007;27(2):430–435.
 38. Nissen SE, et al. Effect of very high-intensity statin 
therapy on regression of coronary atherosclerosis: the 
ASTEROID trial. JAMA. 2006;295(13):1556–1565.
 39. Monetti M, et al. Rosuvastatin displays anti-ath-
erothrombotic and anti-inflammatory proper-
ties in apoE-deficient mice. Pharmacol Res. 2007; 
55(5):441–449.
 40. Tuomisto TT, et al. Simvastatin has an anti-inflam-
matory effect on macrophages via upregulation of 
an atheroprotective transcription factor, Kruppel-
like factor 2. Cardiovasc Res. 2008;78(1):175–184.
 41. Lacut K, Oger E, Le Gal G, Couturaud F, Louis S, 
Leroyer C, Mottier D. Statins but not fibrates are 
associated with a reduced risk of venous throm-
boembolism: a hospital-based case-control study. 
Fundam Clin Pharmacol. 2004;18(4):477–482.
 42. Ramcharan AS, Van Stralen KJ, Snoep JD, Mantel-
Teeuwisse AK, Rosendaal FR, Doggen CJ. HMG-
CoA reductase inhibitors, other lipid-lowering med-
ication, antiplatelet therapy, and the risk of venous 
thrombosis. J Thromb Haemost. 2009;7(4):514–520.
 43. Sorensen HT, et al. Arterial cardiovascular events, 
statins, low-dose aspirin and subsequent risk of 
venous thromboembolism: a population-based 
case-control study. J Thromb Haemost. 2009; 
7(4):521–528.
 44. Aikawa M, et al. An HMG-CoA reductase inhibitor, 
cerivastatin, suppresses growth of macrophages 
expressing matrix metalloproteinases and tis-
sue factor in vivo and in vitro. Circulation. 2001; 
103(2):276–283.
 45. Baetta R, Camera M, Comparato C, Altana C, Eze-
kowitz MD, Tremoli E. Fluvastatin reduces tissue 
factor expression and macrophage accumulation 
in carotid lesions of cholesterol-fed rabbits in the 
absence of lipid lowering. Arterioscler Thromb Vasc 
Biol. 2002;22(4):692–698.
 46. Steiner S, et al. Simvastatin blunts endotoxin-
induced tissue factor in vivo. Circulation. 2005; 
111(14):1841–1846.
 47. Colli S, Eligini S, Lalli M, Camera M, Paoletti R, 
Tremoli E. Vastatins inhibit tissue factor in cul-
tured human macrophages. A novel mechanism of 
protection against atherothrombosis. Arterioscler 
Thromb Vasc Biol. 1997;17(2):265–272.
 48. Kirchhofer D, Moran P, Bullens S, Peale F, Bunting 
S. A monoclonal antibody that inhibits mouse 
tissue factor function. J Thromb Haemost. 2005; 
3(5):1098–1099.
 49. Chou J, Mackman N, Merrill-Skoloff G, Pedersen 
B, Furie BC, Furie B. Hematopoietic cell-derived 
microparticle tissue factor contributes to fibrin 
formation during thrombus propagation. Blood. 
2004;104(10):3190–3197.
 50. Dubuc G, et al. A new method for measurement of 
total plasma PCSK9: clinical applications. J Lipid 
Res. 2010;51(1):140–149.
research article
568	 The	Journal	of	Clinical	Investigation   http://www.jci.org   Volume 122   Number 2   February 2012
 51. Pawlinski R, et al. Hematopoietic and nonhema-
topoietic cell tissue factor activates the coagula-
tion cascade in endotoxemic mice. Blood. 2010; 
116(5):806–814.
 52. Esmon CT. The interactions between inflam-
mation and coagulation. Br J Haematol. 2005; 
131(4):417–430.
 53. Taylor FB, Chang AC, Peer G, Li A, Ezban M, Hed-
ner U. Active site inhibited factor VIIa (DEGR VIIa) 
attenuates the coagulant and interleukin-6 and -8, 
but not tumor necrosis factor, responses of the 
baboon to LD100 Escherichia coli. Blood. 1998; 
91(5):1609–1615.
 54. Pawlinski R, et al. Role of tissue factor and protease-
activated receptors in a mouse model of endotox-
emia. Blood. 2004;103(4):1342–1347.
 55. Kiechl S, et al.  Oxidized phospholipids, 
lipoprotein(a), lipoprotein-associated phospho-
lipase A2 activity, and 10-year cardiovascular 
outcomes: prospective results from the Bru-
neck study. Arterioscler Thromb Vasc Biol. 2007; 
27(8):1788–1795.
 56. Tsimikas S, et al. Increased plasma oxidized phos-
pholipid:apolipoprotein B-100 ratio with concom-
itant depletion of oxidized phospholipids from 
atherosclerotic lesions after dietary lipid-lower-
ing: a potential biomarker of early atherosclero-
sis regression. Arterioscler Thromb Vasc Biol. 2007; 
27(1):175–181.
 57. Sukhova GK, Williams JK, Libby P. Statins reduce 
inflammation in atheroma of nonhuman primates 
independent of effects on serum cholesterol. Arte-
rioscler Thromb Vasc Biol. 2002;22(9):1452–1458.
 58. Casani L, Sanchez-Gomez S, Vilahur G, Badimon 
L. Pravastatin reduces thrombogenicity by mecha-
nisms beyond plasma cholesterol lowering. Thromb 
Haemost. 2005;94(5):1035–1041.
 59. Glynn RJ, et al. A randomized trial of rosuvastatin 
in the prevention of venous thromboembolism.  
N Engl J Med. 2009;360(18):1851–1861.
 60. Cyrus T, et al. Disruption of the 12/15-lipoxygenase 
gene diminishes atherosclerosis in apo E-deficient 
mice. J Clin Invest. 1999;103(11):1597–1604.
 61. Rosenson RS. Statins in atherosclerosis: lipid-low-
ering agents with antioxidant capabilities. Athero-
sclerosis. 2004;173(1):1–12.
 62. Tsimikas S, et al. High-dose atorvastatin reduces 
total plasma levels of oxidized phospholipids and 
immune complexes present on apolipoprotein B-100 
in patients with acute coronary syndromes in the 
MIRACL trial. Circulation. 2004;110(11):1406–1412.
 63. Methe H, Kim JO, Kofler S, Nabauer M, Weis M. 
Statins decrease Toll-like receptor 4 expression 
and downstream signaling in human CD14+ 
monocytes. Arterioscler Thromb Vasc Biol. 2005; 
25(7):1439–1445.
 64. Wang JG, Manly D, Kirchhofer D, Pawlinski R, 
Mackman N. Levels of microparticle tissue fac-
tor activity correlate with coagulation activation 
in endotoxemic mice. J Thromb Haemost. 2009; 
7(7):1092–1098.
 65. Moriarty PM, Luyendyk JP, Gibson CA, Backes JM. 
Effect of low-density lipoprotein apheresis on plas-
ma levels of apolipoprotein e4. Am J Cardiol. 2010; 
105(11):1585–1587.
 66. Parry GC, Erlich JH, Carmeliet P, Luther T, Mack-
man N. Low levels of tissue factor are compatible 
with development and hemostasis in mice. J Clin 
Invest. 1998;101(3):560–569.
 67. Kieft KA, Bocan TM, Krause BR. Rapid on-line 
determination of cholesterol distribution among 
plasma lipoproteins after high-performance 
gel filtration chromatography. J Lipid Res. 1991; 
32(5):859–866.
 68. Thampi P, Stewart BW, Joseph L, Melnyk SB, Hen-
nings LJ, Nagarajan S. Dietary homocysteine pro-
motes atherosclerosis in apoE-deficient mice by 
inducing scavenger receptors expression. Athero-
sclerosis. 2008;197(2):620–629.
 69. Dragovic RA, et al. Sizing and phenotyping of cellu-
lars vesicles using Nanoparticle Tracking Analysis  
[published online ahead of print May 4, 2011]. 
Nanomedicine. 2011;7(6):780–788.
 70. Badeanlou L, et al. Tissue factor-protease-acti-
vated receptor 2 signaling promotes diet-induced 
obesity and adipose inflammation. Nat Med. 2011; 
17(11):1490–1497.
